BOSTON--(BUSINESS WIRE)--Inform Genomics, Inc., a private company focused on developing novel platforms of genomic based personalized medicine products for cancer supportive care and inflammatory diseases, today announced preliminary results from its initial study for its lead product, OnPART™, which is designed to determine an individual’s risk of side-effects associated with chemotherapy regimens based on his or her individual genomic profile. The study utilized advanced Bayesian network technology to identify (single-nucleotide polymorphism) SNP networks associated with common side-effects of chemotherapy regimens. In the plenary session “Molecular Predictors in Supportive Care,” Dr. Stephen T. Sonis, D.M.D., D.M.Sc. who is a co-founder of Inform Genomics and also a Clinical Professor of Oral Medicine at the Harvard School of Dental Medicine, reported that for patients receiving dose-dense doxorubicin, cyclophosphamide, plus paclitaxel (AC+T) a preliminary SNP network correctly identified patients at risk for chemotherapy-induced diarrhea with an accuracy of 96.7% and an area under the receiver operating characteristic (ROC) curve of 0.994.
“We are very encouraged by these early results and they are in line with what we previously demonstrated with a high-degree of precision using our Bayesian network technology to predict oral mucositis with our transplant product,” said Ed Rubenstein, President & CEO of Inform Genomics. “We are excited to see further data demonstrating OnPART’s ability to predict serious toxicities from chemotherapy regimens based on his or her individual genomic profile which may lead to actions to reduce the burden of potentially curable interventions for patients with cancer.”
OnPART™, Oncology Preferences And Risk of Toxicity, is Inform Genomics’ lead platform personalized medicine product for treatment decisions in patients who will receive chemotherapy for colorectal, breast, lung, or ovarian cancer. Based upon response rates and survival, more than one chemotherapy regimen may be considered appropriate care for patients with these common solid tumors, yet the regimens vary widely in their side-effect profiles. OnPART™ is being developed to assess genomic risk for common and often debilitating therapy-related side-effects, including fatigue, nausea and vomiting, diarrhea, oral mucositis, cognitive dysfunction and peripheral neuropathy. The product includes a differentiating factor in personalized medicine, quantifying patient concerns for side-effects, using a copyrighted patient questionnaire (Preference Assessment Inventory©). OnPART™ is expected to provide valuable information for patients and medical oncologists to help clarify critical clinical choices and be commercially available in 2014.
About Cancer Supportive Care
Most patients with cancer receive supportive care as part of their multimodal anti-cancer therapy, regardless of cancer diagnosis, stage of disease, or treatment modality. Common symptoms associated with cancer or its treatments include fatigue, nausea and vomiting, diarrhea, oral mucositis, cognitive dysfunction, and peripheral neuropathy. Some of these conditions are manageable with commercially available medications, while others are the focus of drug development programs. The development of these side-effects may interfere with ongoing anti-cancer treatment, impair patient functioning, negatively impact the patients’ quality of life, and may increase the risk of mortality. Treatment of these side-effects also results in significant costs for payers and providers.
About Inform Genomics
Inform Genomics, Inc. is a private company focused on developing novel platforms of genomic based personalized medicine products for cancer supportive care and inflammatory diseases, including its lead platform product, OnPART™, designed to determine an individual’s risk of side-effects associated with chemotherapy regimens based on his or her individual genomic profile. The company’s business model leverages existing technology in conjunction with proprietary analytic methods for conducting genome-wide association studies. Product development programs will lead to commercial, single source laboratory tests consisting of single-nucleotide polymorphism (SNP) networks that determine the likelihood of individual patient clinical outcomes to drug therapies. The U.S. market opportunity for these differentiated products exceeds $2 billion annually. Inform Genomics is headquartered in Boston, Massachusetts. For more information, please visit www.informgenomics.com.